DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Redwire Corporation ( $RDW )Space infrastructure, defense tech, and execution risk all colliding in 2026

Redwire enters 2026 with a much stronger strategic narrative than it had a year ago. The company is no longer just a small-cap space infrastructure name trying to prove relevance. It now has a larger defense-tech footprint after the Edge Autonomy deal, a more visible sovereign-Europe angle after the Belgian MATTEO award, and a record year-end backlog that gives management a real basis for projecting a major step-up in 2026 revenue.

That is the good side of the story. The harder side is that Redwire still has not earned the right to be treated as a clean execution story. FY2025 showed real top-line progress, but it also exposed how fragile the model remains when development programs run into estimate-at-completion adjustments, integration costs, and heavy cash burn. Revenue grew. Backlog improved. Book-to-bill improved. Yet the company still posted a much larger net loss and very weak free cash flow.

The core question for RDW in 2026 is therefore simple: can Redwire convert strategic relevance into operational credibility? If the answer becomes yes, the stock can look too cheap versus its backlog, government exposure, and 2026 guide. If the answer stays uncertain, the name can remain trapped as an interesting story with inconsistent economics.

POET Technologies Inc ( $POET ) after the LITEON partnership

POET arrived at the industry’s key optical-communications event with fresh news in hand: the new co-development announcement with LITEON, plus demonstrations of Blazar and Starlight products aimed at AI-related optical connectivity. In practical terms, this is the first immediate stage where the market can gauge whether the latest headline gets traction beyond the press release itself.

ROCKET LAB ( $RKLB ) COMPLETE DEEP DIVE march 15 2026

Rocket Lab is no longer just a “small rocket” story. That framing is outdated. The business that reported 2025 results is a broader space infrastructure company with three engines under the hood: Electron launch services, a much larger and increasingly important Space Systems segment, and Neutron, the still-unproven but strategically vital medium-lift program.

Vertex Pharmaceuticals ( $VRTX ) no longer just a cystic fibrosis machine

Vertex Pharmaceuticals remains one of the highest-quality large-cap biotech stories in the market, but the real reason the name deserves a first full Merlintrader deep dive now is not simply scale, profitability or balance-sheet strength. The more important point is that the company has reached a stage where investors can begin to judge whether the long-promised diversification beyond cystic fibrosis is becoming economically meaningful rather than merely aspirational.

Weekly Market Recap & Next Week Prep — March 15, 2026

The week that ended on Friday, March 13, did not deliver a clean “risk-on” or “risk-off” message. It delivered something more difficult and, for active traders, more important: a selective tape in which macro stress was real, energy shock risk was impossible to ignore, but not every pocket of the market reacted in the same way. That distinction matters. A market that falls together can often bounce together. A market that starts separating winners from losers under pressure is usually telling you that stock-picking, catalyst timing and sector choice are starting to matter more than headline beta.

Sidus Space Inc ( $SIDU ) March 14 2026 Deep Dive

Sidus Space Inc (NASDAQ: SIDU) is an innovative space mission enabler operating at the intersection of commercial satellite manufacturing, artificial intelligence-enabled space-based data solutions, and defense technology integration. Founded in 2012 and based on Florida's Space Coast in Merritt Island, the company operates a 35,000-square-foot integrated manufacturing, assembly, and testing facility with direct access to launch infrastructure.

AeroVironment Inc ( $AVAV ) Defense Technology | Uncrewed Systems & Tactical Missiles

AeroVironment (AVAV) operates at the intersection of two powerful secular trends: the electrification and autonomy of military platforms, and the rising geopolitical demand for precision defense systems. As a leader in uncrewed aircraft systems (UAS), loitering munitions (Switchblade series), counter-unmanned aerial systems, and space-based directed energy platforms, the company is uniquely positioned to benefit from a multi-decade modernization cycle driven by conflicts in Ukraine, the Middle East escalation, and NATO expansion.

Satellogic Inc ( $SATL ) Vertically Integrated Earth Observation & Persistent Monitoring March14 DD

Satellogic is one of those names that can look much bigger, much smaller, much safer or much more dangerous depending on the exact week in which an investor or trader meets the story. In a hot tape, the company can be pitched as a pure-play Earth observation platform exposed to sovereign demand, AI-driven geospatial workflows and a possible shift toward more recurring monitoring contracts. In a colder tape, exactly the same company can be described as a low-margin, cash-consuming, serially dilutive small cap whose commercial wins still need to prove that they can scale into a durable business rather than a string of eye-catching press releases. Both sides are seeing a piece of the truth. That is why a SATL report is only useful if it keeps those two realities on the page at the same time.

Intuitive Machines Inc ( $LUNR ) Deep Dive March 14/2026

Intuitive Machines Inc (LUNR) is a diversified space infrastructure company with four core business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products & Infrastructure. Founded in 2013, IM has emerged as a prime contractor for NASA lunar missions, U.S. Department of Defense space architecture programs, and emerging commercial lunar economy players. The company's 2024 milestone—landing the Nova-C lunar lander on the Moon's South Pole region—marked the first crewed-space-capable U.S. lunar return since Apollo 17, positioning IM as the dominant platform for American lunar access for the foreseeable future.

Aldeyra Therapeutics ( $ALDX ): past, present and future around reproxalap and the March 2026 FDA decision

A long-form bilingual deep dive built around the full regulatory arc of Aldeyra, from the first dry-eye filing to the 2025 collapse and the current March 2026 binary setup. The focus here is not only on what happened, but on why the market still cares, what could realistically change if reproxalap is approved, what the damage would look like if it is rejected again, and how retail traders are framing the setup in the final stretch before the decision.

ImmunityBio Inc ( $IBRX ) today’s NK-cell manufacturing milestone is real

Today’s official release from ImmunityBio was about cell-manufacturing execution, not about ANKTIVA sales, not about a fresh FDA approval, and not about a pivotal top-line readout. The company said it has completed manufacturing engineering programs that established a reproducible leukapheresis-to-manufacturing pathway for its autologous M-ceNK platform. In simple English, ImmunityBio is telling the market that it has moved another step from “interesting immunology concept” toward “repeatable cell-therapy process that can be run at scale.”

Firefly Aerospace Inc ( $FLY ) March 12 2026

Thursday’s move in Firefly Aerospace was not just a momentum spike on a cool rocket headline. The market reacted because Alpha Flight 7 checked several boxes at once. Firefly did not merely launch. It reached orbit, delivered a Lockheed Martin technology demonstrator, completed a stage-two engine relight, and used the mission to validate meaningful pieces of its next hardware iteration, Alpha Block II. In the space business, especially for a newer public company still earning its institutional reputation, those are not cosmetic details.

BlackSky (NYSE: $BKSY) — why the story looks stronger in March 2026

BlackSky has turned a familiar speculative space name into something the market is finally trying to reprice as real defense-tech infrastructure. Fourth-quarter numbers were solid, backlog expanded, a new seven-figure NGA Luno delivery order added another official validation point, and then management followed with two operational milestones that matter more than the typical space-company headline: Gen-3 first light arrived within hours, and the fourth Gen-3 satellite was commissioned in less than a week, opening general availability of the company’s best-in-class 35-centimeter imagery and AI-enabled analytics to global customers. The bullish case is no longer based only on a distant dream of “space growth.” It is increasingly built on the idea that BlackSky is becoming a usable, taskable, software-connected intelligence layer for governments that need decisions faster, not just prettier satellite pictures.

Artiva Biotherapeutics Inc ( $ARTV ) March 11th

Artiva Biotherapeutics rallied sharply after its full-year 2025 results and business update put the spotlight back where biotech traders care most: near-term clinical readouts, FDA path visibility, analyst support, and whether the balance sheet is strong enough to carry the story into the next real value-inflection point.